Update on the management of symptoms in schizophrenia: focus on amisulpride

References

• GuoNGuoWGuillinOLaruelleMJavitchJRayportSThe surface D2-binding profile of the atypical antipsychotic drug amisulprideJ Cereb Blood Flow Metabo200727suppl 1PO0302U
   Google Scholar
• KerwinRFrom pharmacological profiles to clinical outcomesInt Clini Psychopharmacol200015suppl 4S1S4
   Google Scholar
• Di GiovanniGDi MascioMDi MatteoVEspositoEEffects of acute and repeated administration of amisulpride, a dopamine D2 D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neuronsJ Pharmacol Exp Ther1998287151579765321
   PubMed Web of Science ®Google Scholar
• PerraultGDepoortereRMorelESangerDScattonBPsychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2 D3 dopamine receptor antagonist activity and limbic selectivityJ Pharmacol Exp Ther1997280173828996184
   PubMed Web of Science ®Google Scholar
• NavarroJManzanequeJVeraFMartin-LopezMSantinLAmisulpride, a presynaptic D2D3, dopamine receptor antagonist, induces catalepsy in miceMed Sci Res1997258551552
   Google Scholar
• MartinotJPaillere-MartinotMPoirierMDao-CastellanaMLoc’hCMaziereBIn vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophreniaSource Psychopharmacol199612412154158
   Web of Science ®Google Scholar
• XiberasXMartinotJ-LMalletLIn vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophreniaJ Clini Psychopharmacol2001212207214
   PubMed Web of Science ®Google Scholar
• StoneJBressanRErlandssonKEllPPilowskyLNon-uniform blockade of intrastriatal D2 D3 receptors by risperidone and amisulpridePsychopharmacol20051804664669
   Web of Science ®Google Scholar
• La FougereCMeisenzahlESchmittGD2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: A 123 I-iodobenzamide SPECT studyJ Nucl Med20054661028103315937316
   PubMed Web of Science ®Google Scholar
• PerraultGSchoemakerHScattonBAmisulpride, an atypical neurolepticEncephale199622spec. iss. 2388767034
   PubMed Web of Science ®Google Scholar
• GessaGDysthymia and depressive disorders: Dopamine hypothesisEur Psychiatry199611suppl 3123s127s
   Web of Science ®Google Scholar
• MollerH-JAmisulpride: Limbic specificity and the mechanism of antipsychotic atypicalityProg Neuropsychopharmacol Biol Psychiatry20032771101111114642970
   PubMed Web of Science ®Google Scholar
• Hamon-VilcotBChaufourSDeschampsCSafety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteersEur J Clini Pharmacol1998545405409
   PubMed Web of Science ®Google Scholar
• PuechAFleurotOReinWmisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs haloperidolActa Psychiatr Scand199898165729696517
   PubMed Web of Science ®Google Scholar
• GrunderGWetzelHSchlosserRNeuroendocrine response to antipsychotics: Effects of drug type and genderBiol Psychiatry199945189979894580
   PubMed Web of Science ®Google Scholar
• LambertMHaroJNovickDOlanzapine vs. other antipsychotics in actual out-patient settings: Six months tolerability results from the European Schizophrenia Out-patient Health Outcomes studyActa Psychiatr Scand2005111323224315701108
   PubMed Web of Science ®Google Scholar
• CacciaSBiotransformation of post-clozapine antipsychotics. Pharmacological implicationsClini Pharmacokinet2000385393414
   PubMed Web of Science ®Google Scholar
• MollerH-JAmisulpride: A review of its efficacy in schizophreniaActa Psychiatr Scand Suppl2000101400172210823307
   PubMedGoogle Scholar
• LauxGAmisulpride for treatment in schizophrenia with positive symptomsPsychopharmakotherapie200073106110
   Google Scholar
• BurnsTBaleRClinical advantages of amisulpride in the treatment of acute schizophreniaJ Int Med Res200129645146611803729
   PubMed Web of Science ®Google Scholar
• CoukellASpencerCBenfieldPAmisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophreniaCNS Drugs199663237256
   Web of Science ®Google Scholar
• WetzelHGrunderGHillertAAmisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology – A double-blind controlled study comparing a selective D2-like antagonist to a mixed D1 D2-like antagonistPsychopharmacol19981373223232
   PubMed Web of Science ®Google Scholar
• FreemanHAmisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: Three efficacy studiesInt Clini Psychopharmacol199712suppl 2S11S17
   Web of Science ®Google Scholar
• AzorinJAcute phase of schizophrenia: Impact of atypical antipsychoticsInt Clini Psychopharmacol200015suppl 4S5S9
   Google Scholar
• LeuchtSBuschRHamannJKisslingWKaneJEarly-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extendedBiol Psychiatry200557121543154915953491
   PubMed Web of Science ®Google Scholar
• Bertolin GuillenJPiles De La FuentePVila NavarroCAmisulpride in delusional disorders. An observational studyArch Psiquiatria2005684301308
   Google Scholar
• ScattonBClaustreYCudennecAAmisulpride: From animal pharmacology to therapeutic actionInt Clini Psychopharmacol199712suppl 2S29S36
   Web of Science ®Google Scholar
• CudennecAFageDBenavidesJEffects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the ratBrain Res19977682572659369323
   PubMed Web of Science ®Google Scholar
• DanionJReinWFleurotOImprovement of schizophrenic patients with primary negative symptoms treated with amisulprideAm J Psychiatry199915661061610200742
   PubMed Web of Science ®Google Scholar
• MollerHVan PraagHAufdembrinkeBNegative symptoms in schizophrenia: considerations for clinical trialsPsychopharmacol1994115221228
   Web of Science ®Google Scholar
• LooHPoirier-LittreMTheronMAmisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophreniaBr J Psychiatry199717018229068769
   PubMed Web of Science ®Google Scholar
• BoyerPLecrubierYPeuchATreatment negative symptoms in schizophrenia with amisulprideBr J Psychiatry199516668727894879
   PubMed Web of Science ®Google Scholar
• ReinWTurjanskiSClinical update on amisulpride in deficit schizophreniaInt Clini Psychopharmacol199712suppl 2S19S27
   Web of Science ®Google Scholar
• MollerHBoyerPFleurotOReinWImprovement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidolPsychopharmacol19971324396401
   Web of Science ®Google Scholar
• PeuskensJBechPMollerH-JBaleRFleurotOReinWAmisulpride vs risperidone in the treatment of acute exacerbations of schizophreniaPsychiatry Res199988210711710622347
   PubMed Web of Science ®Google Scholar
• SpellerJBarnesTCursonDPantelisCAlbertsJOne-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidolBr J Psychiatry19971715645689519098
   PubMed Web of Science ®Google Scholar
• ColonnaLSaleemPDondey-NouvelLReinWLong-term safety and efficacy of amisulpride in subchronic or chronic schizophreniaInt Clini Psychopharmacol20001511322
   PubMed Web of Science ®Google Scholar
• LeuchtSAmisulpride – A selective dopamine antagonist and atypical antipsychotic: Results of a meta-analysis of randomized controlled trialsInt J Neuropsychopharmacol20047suppl 1S15S2014972080
   PubMed Web of Science ®Google Scholar
• VaivaGThomasPLlorcaPSPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndromePsychiatry Res200211512374812165364
   PubMed Web of Science ®Google Scholar
• StorosumJElferinkAVan ZwietenBVan StrikRHoogendijkWBroekmansAAmisulpride: Is there a treatment for negative symptoms in schizophrenia patients?Schizophr Bull200228219320112693427
   PubMed Web of Science ®Google Scholar
• OlieJ-PSpinaEMurraySYangRZiprasidone and amisulpride effectively treat negative symptoms of schizophrenia: Results of a 12-week, double-blind studyInt Clini Psychopharmacol2006213143151
   PubMed Web of Science ®Google Scholar
• LecrubierYQuintinPBouhassiraMPerrinELancrenonSThe treatment of negative symptoms and deficit states of chronic schizophrenia: Olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trialActa Psychiatrica Scand20061145319327
   Web of Science ®Google Scholar
• ChiaieRCaliariPChronic mild depressive symptoms: Rational use of amisulprideRivista di Psichiatria199732suppl 67793
   Google Scholar
• PaniLGessaGThe role of dopamine in the biological basis of dysthymiaItal J Psychiatr Behav Sci19988159
   Google Scholar
• PappMWieronskaJAntidepressant-like activity of amisulpride in two animal models of depressionJ Psychopharmacol2000141465210757253
   PubMed Web of Science ®Google Scholar
• BoyerPLecrubierYAtypical antipsychotic drugs in dysthymia: Placebo controlled studies of amisulpride versus imipramine, versus amineptineEur Psychiatry199611suppl 3135s140s
   Web of Science ®Google Scholar
• SmeraldiEHaefeleECrespiGCasadeiGBiondiFVigorelliEAmisulpride versus fluoxetine in dysthymia: Preliminary results of a double-blind comparative studyEur Psychiatry199611suppl 3141s143s
   Web of Science ®Google Scholar
• Paes De SousaMAmisulpride in dysthymia: Results of a naturalistic study in general practiceEur Psychiatry199611suppl 3145s147s
   Web of Science ®Google Scholar
• BogettoFBarzegaGBellinoSMainaGRavizzaLDrug treatment of dysthymia: A clinical studyRivista di Psichiatria199732115
   Google Scholar
• BoyerPLecrubierYStalla-BourdillonAFleurotOAmisulpride versus amineptine and placebo for the treatment of dysthymiaNeuropsychobiol19993912532
   PubMed Web of Science ®Google Scholar
• RavizzaLAmisulpride in medium-term treatment of dysthymia: A six-month, double-blind safety study versus amitriptylineJ Psychopharmacol199913324825410512080
   PubMed Web of Science ®Google Scholar
• RoccaPFonzoVRavizzaLA comparison of paroxetine and amisulpride in the treatment of dysthymic disorderJ Affect Disord200270331331712128243
   PubMed Web of Science ®Google Scholar
• MontgomerySDopaminergic deficit and the role of amisulpride in the treatment of mood disordersInt Clini Psychopharmacol200217suppl 4S9S19
   PubMed Web of Science ®Google Scholar
• CeskovaEDeniban in the treatment of dysthymiaCeska Slove Psychiatr200710327379
   Google Scholar
• ZanardiRSmeraldiEA double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymiaEur Neuropsychopharmacol200616428128716316746
   PubMed Web of Science ®Google Scholar
• LecrubierYBoyerPTurjanskiSReinWAmilsulpride versus imipramine and placebo in dysthymia and major depressionJ Affect Disord1997432951039165379
   PubMed Web of Science ®Google Scholar
• AmoreMJoriMFaster response on amisulpride 50 mg versus sertraline 50–100 mg in patients with dysthymia or double depression: A randomized, double-blind, parallel group studyInt Clini Psychopharmacol2001166317324
   Web of Science ®Google Scholar
• CassanoGJoriMEfficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: A randomized, double-blind, parallel group studyInt Clini Psychopharmacol20021712732
   Web of Science ®Google Scholar
• SmeraldiEAmisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative studyJ Affect Disord199848147569495601
   PubMed Web of Science ®Google Scholar
• CanalMLegangneuxEVan LierJVan VietACoulouvratCLack of effect of amisulpride on the pharmacokinetics and safety of lithiumInt J Neuropsychopharmacol20036210310912890302
   PubMed Web of Science ®Google Scholar
• SvestkaJNew psychotropics: Amisulpride – Atypical compound in the group of 2nd generation antipsychoticsPsychiatrie200043191200
   Google Scholar
• PeuskensJMollerHPuechAAmisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidoneEur Neuropsychopharmacol200212405310
   Web of Science ®Google Scholar
• VanelleJ-MDoukiSA double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depressionEur Psychiatry200621852353017113759
   PubMed Web of Science ®Google Scholar
• KimS-WShinL-SKimJ-MAmisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trialProgr in Neuropsychopharmacol Biol Psychiatry200731715041509
   Web of Science ®Google Scholar
• HafnerHMaurerKRuhmannSEarly detection and secondary prevention of psychosis: Facts and visionsEur Archi Psychiatry Clini Neurosci20042542117128
   PubMed Web of Science ®Google Scholar
• BechdolfARuhmannSWagnerMInterventions in the initial prodromal states of psychosis in Germany: Concept and recruitmentBr J Psychiatry2005187suppl 48s45s48
   Web of Science ®Google Scholar
• RuhmannSBechdolfAKuhnKAcute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosisBr J Psychiatry2007191suppl 51s88s95
   Web of Science ®Google Scholar
• MurphyBStuartAWadeDCottonSMcGorryPEfficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: A pilot studyHum Psychopharmacol200621851151717066489
   PubMed Web of Science ®Google Scholar
• KahnRFleischhackerWBoterHEffectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreni-form disorder: an open randomised clinical trialLancet2008371961108581097
   Google Scholar
• KontaxakisVHavaki-KontaxakiBFerentinosPPaplosKSoldatosCSwitching to amisulpride monotherapy for treatment-resistant schizophreniaEur Psychiatry200621321421716531015
   PubMed Web of Science ®Google Scholar
• CroissantBHermannDOlbrichRSaving potential of clozapine due to combination with amisulpridePsychopharmakotherapie200183128130
   Google Scholar
• KampfPAgelinkMMassRJohnHSchaferINaberDAmisulpride in addition to clozapine: A retrospective study indicates improved efficacy and good tolerabilityGer J Psychiatry2003636468
   Google Scholar
• ZinkMKnopfUHennFThomeJCombination of Clozapine and Amisulpride in Treatment-Resistant Schizophrenia – Case Reports and Review of the LiteraturePharmacopsychiatry2004b371263114750045
   PubMed Web of Science ®Google Scholar
• CookBHoogenboomGCombined use of amisulpride and clozapine for patients with treatment-resistant schizophreniaAustralas Psychiatry2004121747615715745
   PubMedGoogle Scholar
• MunroJMatthiassonPOsborneSAmisulpride augmentation of clozapine: An open non-randomized study in patients with schizophrenia partially responsive to clozapineActa Psychiatr Scand2004110429229815352931
   PubMed Web of Science ®Google Scholar
• FrickAKopitzJKressKBergemannNClozapine raises plasma levels of amisulpridePsychopharmakotherapie20031012831
   Google Scholar
• ZinkMHennFThomeJCombination of amisulpride and olanzapine in treatment-resistant schizophrenic psychosesEur Psychiatry2004a191565814969782
   PubMed Web of Science ®Google Scholar
• ChanJSweetingMCombination therapy with non-clozapine atypical antipsychotic medication: A review of current evidenceJ Psychopharmacol200721665766417092976
   PubMed Web of Science ®Google Scholar
• LernerVBergmanJBorokhovALoewenthalUMiodownikCAugmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapyClini Neuropharmacol20052826671
   Web of Science ®Google Scholar
• ZinkMDressingHAugmenting atypical antipsychotic medications with clozapinNervenarzt20057691092110215782324
   PubMed Web of Science ®Google Scholar
• ZiegenbeinMSiebererMKuenzelHKroppSAugmentation of Clozapine with amisulpride in patients with treatment-resistant schizophrenia an open clinical studyGer J Psychiatry2006911722
   Google Scholar
• KoenLNiehausDSchulteAMullerJEmsleyROosthulzenPAmisulpride as adjunct to clozapine in treatment-resistant schizophrenia and schizoaffective disorder: An open-label pilot studyAfr J Psychiatry (Johannesbg)20061211720
   Google Scholar
• AssionH-JReinboldHLemanskiSBasilowskiMJuckelGAmisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trialPharmacopsychiatry2008411242818203048
   PubMed Web of Science ®Google Scholar
• GencYTanerECandansayarSComparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized studyAdv Ther200724111317526456
   PubMed Web of Science ®Google Scholar
• KreininANovitskiDWeizmanAAmisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: A randomized, double-blind, placebo-controlled cross-over studyInt Clini Psychopharmacol200621299103
   Web of Science ®Google Scholar
• SockalingamSShammiCRemingtonGClozapine-induced hypersalivation: A review of treatment strategiesCan J Psychiatry200752637738417696024
   PubMed Web of Science ®Google Scholar
• MattilaMPatatASeppalaTSingle oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjectsEur J Clin Pharmacol19965121611668911882
   PubMed Web of Science ®Google Scholar
• PatatARosenzweigPMigetNAllainHGandonJ-MEffects of 50 mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjectsFund Clini Pharmacol1999135582594
   Web of Science ®Google Scholar
• PerettiCDanionJKauffmann-MullerFGrangeDPatatARosenzweigPEffects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteersPsychopharmacol19971314329338
   Web of Science ®Google Scholar
• PeraultMBergougnanLPaillatAZieleniukIRosenzweigPVandelBLack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteersHum Psychopharmacol1998137493500
   Web of Science ®Google Scholar
• RamaekersJLouwerensJMuntjewerffNPsychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychoticJ Clini Psychopharmacol1999193209221
   PubMed Web of Science ®Google Scholar
• LegangneuxEMcEwenJWesnesKThe acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteersJ Psychopharmacol200014216417110890311
   PubMed Web of Science ®Google Scholar
• RosenzweigPCanalMPatatABergougnanLZieleniukIBianchettiGA review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteersHum Psychopharmacol200217111312404702
   PubMed Web of Science ®Google Scholar
• GibbsANaudtsKSpencerEDavidAThe role of dopamine in attentional and memory biases for emotional informationAm J Psychiatry20071641016016093
   Web of Science ®Google Scholar
• MorrensMHulstijnWSabbeBThe effects of atypical and conventional antipsychotics on reduced processing speed and psychomotor slowing in schizophrenia: A cross-sectional exploratory studyClini Ther2008304684692
   Web of Science ®Google Scholar
• WangY-TChiuN-YJouS-HEffects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidoneInt J Psychiatry Clini Pract2008123180186
   Web of Science ®Google Scholar
• TysonPRobertsKMortimerAAre the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors?Int J Neurosci2004114659361115204055
   PubMed Web of Science ®Google Scholar
• WagnerMQuednowBWesteideJSchlaepferTMaierWKuhnK-UCognitive improvement in schizophrenic patients does not require a serotonergic mechanism: Randomized controlled trial of olanzapine vs amisulprideNeuropsychopharmacol2005302381390
   PubMed Web of Science ®Google Scholar
• MortimerAJoyceEBalasubramaniamDChoudharyPSaleemPTreatment with amisulpride and olanzapine improve neuropsychological function in schizophreniaHum Psychopharmacol200722744545417691076
   PubMed Web of Science ®Google Scholar
• ChabannesJPelissoloAFarahSGerrardDTreatment of psychosis with productive symptoms: Efficacy and safety of amisulprideEncephale19982443863929809244
   PubMed Web of Science ®Google Scholar
• CarrierePBonhommeDLemperiereTAmisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: Results of a multicentre, double-blind study (the amisulpride study group)Eur Psychiatry200015532132911032464
   PubMed Web of Science ®Google Scholar
• SaleemPOlieJLooHSocial functioning and quality of life in the schizophrenic patient: Advantages of amisulprideInt Clini Psychopharmacol200217118
   Web of Science ®Google Scholar
• SurguladzeSPatelAKerwinRKnappMTravisMCost analysis of treating schizophrenia with amisulpride: Naturalistic mirror image studyProg in Neuropsychopharmacol Biol Psychiatry200529451752215866352
   PubMed Web of Science ®Google Scholar
• TysonPLawsKFlowersKTysonAMortimerACognitive function and social abilities in patients with schizophrenia: Relationship with atypical antipsychoticsPsychiatry Clini Neurosci2006604473479
   Web of Science ®Google Scholar
• LambertMNaberDEichFSchachtMLindenMSchimmelmannBRemission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulprideActa Psychiatri Scand20071110625113
   Google Scholar
• FalkaiPVogeleyKChances of new atypical substancesFortschr Neurol Psychiatr200068suppl 1S32S3710907611
   PubMed Web of Science ®Google Scholar
• GeddesJFreemantleNHarrisonPBebbingtonPAtypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysisBMJ200032172731371137611099280
   PubMed Web of Science ®Google Scholar
• BarnettDGuidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophreniaNational Institute for Clinical ExcellenceLondon200243
   Google Scholar
• HugenholtzGHeerdinkEStolkerJMeijerWEgbertsANolenWHaloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: Comparison with officially recommended dosesSource J Clin Psychiatry2006676897903
   Web of Science ®Google Scholar
• CeskovaEAmisulpride – A new benzamide antipsychotic of the second generationCeska a Slovenska Psychiatrie2000968411415
   Google Scholar
• PeuskensJSwitching approach in the management of schizophrenia patientsInt Clini Psychopharmacol200015suppl 4S15S19
   Google Scholar
• PaniLVillagranJKontaxakisVAlptekinKPractical issues with amisulpride in the management of patients with schizophreniaClini Drug Investig2008288465477
   Web of Science ®Google Scholar
• BurnsTChabannesJDemyttenaereKSwitching antipsychotic medications: General recommendations and switching to amisulprideCurr Med Res Opin200218420120812201620
   PubMed Web of Science ®Google Scholar
• HaroJNovickDBelgerMJonesPAntipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophreniaEur Psychiatry2006211414716414249
   PubMed Web of Science ®Google Scholar
• KahnRFleischhakerWBoterHEffectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet200837196181085109718374841
   PubMed Web of Science ®Google Scholar
• LindenMScheelTEichF-XImprovement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulprideJ Psychopharmacol200620681582316401647
   PubMed Web of Science ®Google Scholar
• NussPHummerMTessierCThe use of amisulpride in the treatment of acute psychosisTher Clini Risk Manage200731311
   PubMedGoogle Scholar
• LecrubierYIs amisulpride an ‘atypical’ atypical antipsychotic agent?Int Clin Psychopharmacol200015suppl 4S21S2611252520
   PubMed Web of Science ®Google Scholar
• CurranMPerryCAmisulpride: A review of its use in the management of schizophreniaDrugs200161142123215011735643
   PubMed Web of Science ®Google Scholar
• LeuchtSPitschel-WalzGEngelRKisslingWAmisulpride, an unusual “atypical” antipsychotic: A meta-analysis of randomized controlled trialsAm J Psychiatry2002159218019011823257
   PubMed Web of Science ®Google Scholar
• DavisJChenNGlickIA meta-analysis of the efficacy of second-generation antipsychoticsArch Gen Psychiatry200360655356412796218
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRLiCDavisJSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• NaberDArltJLambertMAmisulpride: A safe and effective option for the long-term treatment of patients with schizophreniaInt J Psychiatry Clini Pract200373167175
   Web of Science ®Google Scholar
• Herrera-EstrellaMApiquianRFresanASanchez-TorresIInstitution. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: A prospective open-label studyBMC Psychiatry2005522
   Google Scholar
• McKeageKPloskerGAmisulpride: A review of its use in the management of schizophreniaCNS Drugs2004181393395615521794
   PubMed Web of Science ®Google Scholar
• ReinWCoulouvratCDondey-NouvelLSafety profile of amisulpride in short- and long-term useActa Psychiatr Scand2000Suppl 1014002327
   Web of Science ®Google Scholar
• CurranMPerryCSpotlight on amisulpride in schizophreniaCNS Drugs200216320721111888341
   PubMed Web of Science ®Google Scholar
• LindenMScheelTEichFDosage finding and outcome in the treatment of schizophrenic inpatients with amilsupride. Results of a drug utilization observation studyHum Psychopharmacol200419211111914994321
   PubMed Web of Science ®Google Scholar
• MullerMWetzelHEichF-XReinWPuechABenkertODose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophreniaJ Clini Psychopharmacol2002226554560
   Web of Science ®Google Scholar
• SechterDPeuskensJFleurotOAmisulpride vs. risperidone in chronic schizophrenia: Results of a 6-month double-blind studyNeuropsychopharmacol200227610711081
   PubMed Web of Science ®Google Scholar
• HwangTLeeS-MSunH-JAmisulpride versus risperidone in the treatment of schizophrenic patients: A double-blind pilot study in TaiwanJ Form Med Assoc200310213036
   PubMed Web of Science ®Google Scholar
• MortimerAHow do we choose between atypical antipsychotics? The advantages of amisulprideInt J Neuropsychopharmacol20047suppl 1S21S2514972081
   PubMed Web of Science ®Google Scholar
• HoferARettenbacherMEdlingerMOutcomes in schizophrenia outpatients treated with amisulpride or olanzapinePharmacopsychiatry20074011817327953
   PubMed Web of Science ®Google Scholar
• MotlovaLSpanielFHoschlCBalonRAre there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?Ann Clini Psychiatry2007192133143
   Google Scholar
• VohoraDAtypical antipsychotic drugs: Current issues of safety and efficacy in the management of schizophreniaCurr Opin Investig Drugs200787531538
   Google Scholar
• MortimerAMartinSLooHPeuskensJA double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophreniaInt Clini Psychopharmacol20041926369
   PubMed Web of Science ®Google Scholar
• ManschreckTBoshesRThe CATIE Schizophrenia Trial: results, impact, controversyMol Psychiatry200724525817925796
   PubMed Web of Science ®Google Scholar
• LewisSLiebermanJCATIE and CUtLASS: Can we handle the truth?Br J Psychiatry2008192316116318310570
   PubMed Web of Science ®Google Scholar
• LewisSDaviesLJonesPRandomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatmentHealth Technol Assess20061017194
   Web of Science ®Google Scholar